Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966053 | 1.00 | CYP1A2 (0.50) | CYP1A2ALDH1A1ADRA2A | |
| SCHEMBL1143606 | 0.94 | CYP1A2 (0.58) | CYP1A2ALDH1A1ADRA2A | |
| SCHEMBL445540 | 0.87 | — | — | |
| SCHEMBL3180256 | 0.87 | — | — | |
| SCHEMBL2829694 | 0.87 | — | — | |
| SCHEMBL19376421 | 0.87 | CYP1A2 (0.57) | CYP1A2ALDH1A1ADRA2A | |
| Hydrochloric Acid SCHEMBL29056655 | 0.85 | CYP1A2 (0.52) | CYP1A2ALDH1A1ADRA2A | |
| Hydrochloric Acid SCHEMBL2673742 | 0.85 | CYP1A2 (0.52) | CYP1A2ALDH1A1ADRA2A | |
| Hydrochloric Acid SCHEMBL29056653 | 0.85 | CYP1A2 (0.52) | CYP1A2ALDH1A1ADRA2A | |
| Hydrochloric Acid SCHEMBL6778419 | 0.85 | CYP1A2 (0.52) | CYP1A2ALDH1A1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763938-B2 | Substituted quinoxalines as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-09-19 | — | — | US | claimed |
| US-20160317533-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | MERCK PATENT GMBH (DE) | 2016-11-03 | — | — | US | claimed |
| US-20150374687-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | MERCK PATENT GMBH (DE) | 2015-12-31 | — | — | US | claimed |
| EP-2953939-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | Merck Patent GmbH (DE) | 2015-12-16 | — | — | EP | claimed |
| WO-2014121885-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | claimed |
| US-20110288057-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2011-11-24 | — | — | US | claimed |
| EP-2342173-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | Novartis AG (CH) | 2011-07-13 | — | — | EP | claimed |
| WO-2010043584-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | NOVARTIS AG (CH) | 2010-04-22 | — | — | WO | claimed |
| US-7060700-B2 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | claimed |
| EP-1163212-B1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-31 | — | — | EP | claimed |
| US-6548514-B1 | Inhibitors of p38 kinase/cytokine suppressive binding protein (CSBP)/reactivating kinase (RK); 1-((pyridyl)aminocarbonyl)-3-((hetero)arylaminocarbonyl)benzene derivatives; treating cytokine related diseases and disorders | ASTRAZENECA AB (SE) | 2003-04-15 | — | — | US | claimed |
| JP-2002539187-A | — | — | 2002-11-19 | — | — | JP | claimed |
| US-6455520-B1 | TUMOR NECROSIS FACTOR AND INTERLEUKIN INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIALLERGENS; BONE DISORDERS | ASTRA ZENECA AB (SE) | 2002-09-24 | — | — | US | claimed |
| US-6432949-B1 | Amide derivatives useful as inhibitors of the production of cytokines | ASTRAZENECA AB (SE) | 2002-08-13 | — | — | US | claimed |
| EP-1163212-A1 | AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2001-12-19 | — | — | EP | claimed |
| EP-1115707-A1 | BENZAMIDE DERIVATIVES AND THER USE AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-07-18 | — | — | EP | claimed |
| EP-1102750-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2000055120-A1 | AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-09-21 | — | — | WO | claimed |
| WO-2000018738-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-04-06 | — | — | WO | claimed |
| WO-2000007991-A1 | AMIDE DERIVATIVES USEFUL AS INHIBITORS OF THE PRODUCTION OF CYTOKINES | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374687-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | GRM4, GRIK4, GRIA4 | CYP1A2 4495/4885ALDH1A1 4729/4885ADRA2A 1339/4885 |
| US-20110288057-A1 | SALICYLIC ACID DERIVATIVES BEING FARNESYL PYROPHOSPHATE SYNTHASE ACTIVITY INHIBITORS | FDPS, GGPS1, COASY | CYP1A2 1609/4885ALDH1A1 643/4885ADRA2A 4657/4885 |
| US-20160317533-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | GRM4, GRIA4, GRIK4 | CYP1A2 3946/4885ALDH1A1 4335/4885ADRA2A 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.